Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 17c
November 5, 2019 7:37 AM ESTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.63), $0.17 better than the analyst estimate of ($0.80).
I am pleased with the significant progress we have made in the third quarter across our commercial, regulatory, and clinical initiatives, said Dr. Sharon Mates, Chairman and CEO of... More
